Biomarkers in drug development

Annals of Oncology

Volumn 19, Issue SUPPL. 5, 2008, Pages

  Zwierzina, H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; TRASTUZUMAB; VASCULOTROPIN INHIBITOR; TUMOR MARKER; TUMOR PROTEIN;

CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DISEASE MARKER; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEUTROPENIA; PATIENT MONITORING; PATIENT SELECTION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; ARTICLE; BIOPSY; DRUG DESIGN; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY;

BIOPSY; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 49049118310     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn309     Document Type: Conference Paper

References (19)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
2. U.S. Food and Drug Administration. Innovation or stagnation: Challenge and opportunity on the critical path to new medical products. Rockville, MD: U.S. Food and Drug Administration, U.S. Department of Health and Human Services; March 2004. www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html
3. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nat Rev Cancer 2002; 2: 19-27.
4. Bailey LR, Kris M, Wolf M et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 2003; 44: 1362 (Abstr LB-170).
5. Hirsch F, Varella-Garcia M, Cappuzzo F et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007; 18: 752-760.
6. Hirsch FR, Varella-Garcia M, Bunn PA et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-3807.
7. Hirsch FR, Varella-Garcia M et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-5042.
8. Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
9. Ichikawa W, Araki K, Fujita K et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst 2008; 100: 224-225.
10. Workman P, Aboagye EO, Chung Y-L et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 2006; 98: 580-598.
11. Kelloff GJ, Sigman CC. New science-based endpoints to accelerate oncology drug development. Eur J Cancer 2005; 41: 491-501.
12. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445-2459.
13. U.S. Food and Drug Administration. Innovation or stagnation: Challenge and opportunity on the critical path to new medical products. Rockville, MD: U.S. Food and Drug Administration, U.S. Department of Health and Human Services; March 2004. www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html#execsummary
14. Banks RE, Dunn MJ, Hochstrasser DF et al. Proteomics: New perspectives, new biomedical opportunities. Lancet 2000; 18: 1749-1756.
15. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Oncol 2003; 3: 267-275.
16. Skvortsov S, Sarg B, Loeffler-Ragg J et al. Different proteome pattern of EGFR positive colorectal cancer cell lines responsive and non-responsive to C225 antibody treatment. Mol Cancer Ther 2004; 3: 1-8.
17. Schwartz SA, Weil RJ, Thompson RC et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005; 65: 7674-7681.
18. Taguchi F, Solomon B, Gregorc V et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study. J Natl Cancer Inst 2007; 99: 838-846.
19. Jayson G, Jackson A, Mulatero C et al. Molecular and biological evaluation of HuMV833 anti-VEGF antibody: Resistance mechanisms in anti-angiogenic therapy. J Natl Cancer Inst 2002; 94: 1484-1493.